Additional file 2 of An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
Figshare January 1, 2026 Jesse Dallery, Jennifer L. Miller, Jeff Boissoneault et al.
No Summary
Peter R. Guzzo
4 papers in the library · publishing 2023-2026
Papers
Additional file 1 of An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
Figshare January 1, 2026 Jesse Dallery, Jennifer L. Miller, Jeff Boissoneault et al.
No Summary
An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
Figshare January 1, 2026 Jesse Dallery, Jennifer L. Miller, Jeff Boissoneault et al.
A single 25 mg dose of psilocybin, combined with Acceptance and Commitment Therapy, was tested in five adults with binge-eating disorder. The treatment was well tolerated with no serious adverse events. All participants reported reduced binge eating frequency that lasted through 14 weeks. Improvements also occurred in depression, anxiety, and psychological inflexibility. Three participants lost weight and reduced waist circumference. Brain scans showed increased activity in regions linked to cognitive control and self-awareness when viewing processed versus unprocessed food cues. Because the study was small and open-label, causality cannot be determined, but the results support larger controlled trials.
Intravenous psilocybin administration attenuates mechanical hypersensitivity in a rat model of chronic pain
bioRxiv (Cold Spring Harbor Laboratory) August 28, 2023 Nicholas Kolbman, Tiecheng Liu, Peter R. Guzzo et al. preprint
A single intravenous dose of psilocybin (1 mg/kg or 10 mg/kg) reduced mechanical hypersensitivity in rats for 28 days after formalin-induced chronic pain, but had only a limited effect on thermal hyperalgesia. Formalin injection caused thermal hyperalgesia and bilateral mechanical hypersensitivity in all rats. Psilocybin significantly attenuated the mechanical hypersensitivity throughout the 28-day testing period, while thermal hyperalgesia was reduced only on days 1, 3, 5, and 21. These results suggest psilocybin may have potential for treating chronic pain, though its effects on different pain types vary.